Poolbeg Pharma expands its patent portfolio for POLB 002
(POLB ) said its patent portfolio in Europe, US and elsewhere for POLB 002, an intranasally administered RNA-based immunotherapy for respiratory virus infections, is growing as part of its overall strategy to enhance the protection of the company’s assets.
The infectious disease pharmaceutical company told investors that the European Patent Office has granted another important patent in the company’s POLB 002 patent family, which protects the use of a defective interfering (DI) influenza virus against infection by influenza.
Earlier this year in January 2022, Poolbeg Pharma secured an exclusive licence for its dual antiviral prophylactic and therapeutic candidate, which is being developed as POLB 002.
To date, data has suggested that the asset could provide pan-viral protection from respiratory virus infections including influenza, respiratory syncytial virus (RSV), SARS-CoV-2 and others.
As a nasally administered and rapidly effective prophylactic antiviral candidate, it could potentially provide an effective solution for protecting different at-risk patient populations.
Poolbeg’s POLB 002 candidate works by triggering nasal cells into an antiviral state using DI influenza that resembles the infectious influenza virus but doesn’t have the ability to replicate and therefore can provoke an appropriate immune response but does not cause an infection.
Poolbeg said it will continue to work with its patent advisors to broaden and expand the patent family, including the method by which defective interfering antiviral agents can be identified.
The Company highlighted to investors today that discussions with patent authorities in other jurisdictions, including the US, are continuing with further positive announcements expected following a recent ‘Notice of Allowance’ communication from the US patent authorities.
Poolbeg said the development of POLB 002 and these patent updates come at “a critical time” with a global focus on respiratory virus infections, and when such viruses are considered a top five global killer, resulting in more than three million annual deaths.
The pandemic potential of influenza continues to be monitored closely by the global health authorities, while the World Health Organisation (WHO) and infectious hazard experts have guided that there is statistical certainty that a future influenza pandemic can be expected.
The CDC has advised that early action and effective preparedness are “absolutely essential” to mitigating risk, hence highlighting the importance of developing vaccines, prophylactics and antiviral treatments against viruses; with pan-viral products offering an important solution.
Commenting, Dr Jeremy Skillington, CEO of Poolbeg Pharma, told investors: “The granting of this patent marks an important step in our development and protection of this important respiratory virus disease treatment. Data for POLB 002 shows it is able to both prevent viral infections and rapidly reduce viral loads where infection has occurred, improving disease symptoms and aiding recovery. This makes it an attractive candidate in a market where a significant unmet need for the treatment of most respiratory virus infections still exists.”
He added: “Our patent portfolio in Europe, US and elsewhere for POLB 002 are growing as part of our overall strategy to enhance the protection of Poolbeg’s assets and we look forward to updating shareholders on future patent grants.”
Follow News & Updates from :
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.